Searched for: in-biosketch:true
person:izmirp01
Factors associated with long-term cardiac dysfunction in neonatal lupus
Saxena, Amit; Izmirly, Peter M; Bomar, Rebecca P; Golpanian, Rachel Shireen; Friedman, Deborah M; Eisenberg, Ruth; Kim, Mimi Y; Buyon, Jill P
OBJECTIVES/OBJECTIVE:Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality; however, there is minimal information on long-term outcomes of affected individuals. This study was initiated to evaluate the presence of and the risk factors associated with cardiac dysfunction in NL after birth in multiple age groups to improve counselling, to further understand pathogenesis and to provide potential preventative strategies. METHODS:Echocardiogram reports were evaluated in 239 individuals with cardiac NL: 143 from age 0-1 year, 176 from age >1-17 years and 64 from age >17 years. Logistic regression analyses evaluated associations of cardiac dysfunction at each age group with demographic, fetal and postnatal factors, using imputation to address missing data. RESULTS:Cardiac dysfunction was identified in 22.4% at age 0-1 year, 14.8% at age >1-17 years and 28.1% at age >17 years. Dysfunction in various age groups was significantly associated with male sex, black race, lower fetal heart rates, fetal extranodal cardiac disease and length of time paced. In 106 children with echocardiograms at ages 0-1 year and >1-17 years, 43.8% with dysfunction at age 0-1 year were also affected at age >1-17 years, while the others reverted to normal. Of children without dysfunction at age 0-1 year, 8.9% developed new dysfunction between ages >1 and 17 years. Among 34 with echocardiograms at ages >1-17 years and >17 years, 6.5% with normal function at age >1-17 years developed dysfunction in adulthood. CONCLUSIONS:Risk factors in fetal life can influence cardiac morbidity into adulthood.Although limited by a small number of cases, cardiac dysfunction in the first year often normalises by later childhood. New-onset dysfunction, although rare, can occur de novo after the first year.
PMID: 31672776
ISSN: 1468-2060
CID: 4162732
Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis
Nusbaum, Julie S; Mirza, Ibraheem; Shum, Justine; Freilich, Robert W; Cohen, Rebecca E; Pillinger, Michael H; Izmirly, Peter M; Buyon, Jill P
Systemic lupus erythematosus (SLE) is a chronic, multiorgan, systemic autoimmune disease that is more common in women than men and is typically diagnosed during reproductive age, necessitating sex-specific considerations in care. In women there is no substantive evidence to suggest that SLE reduces fertility, but subfertility may occur as a result of active disease, immunosuppressive drugs, and age-related declines in fertility related to delays in childbearing. Although pregnancy outcomes have improved, SLE still poses risks in pregnancy that contribute to poorer maternal and fetal outcomes. Cyclophosphamide, an important agent for the treatment of severe or life-threatening lupus, may adversely affect fertility, particularly with increases in dose and patient age. Fertility preservation techniques are therefore an important consideration for women and men before cytotoxic treatment. There is mixed evidence as to whether exogenous estrogen in the form of oral contraceptive pills or hormone replacement therapy may increase the risk for the development of SLE, but among women with SLE already diagnosed, combined oral contraceptive pills and hormone replacement therapy do not confer risk for severe flare and remain important in reproductive care. The higher incidence of SLE in women may nonetheless be attributable to effects of endogenous estrogen, as well as failures in X chromosome inactivation, increased Toll-like receptor gene products, and changes in microRNA function. A greater appreciation of the biological underpinnings and consequences of sex differences in SLE may lead to more targeted treatments and improved outcomes for patients with SLE.
PMID: 32029091
ISSN: 1942-5546
CID: 4300592
Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis [Meeting Abstract]
Azzouz, Doua; Chen, Ze; Li, Zhi; Izmirly, Peter; Deng, Jing; Fenyo, David; Buyon, Jill; Alekseyenko, Alexander; Silverman, Gregg
ISI:000587568506066
ISSN: 2326-5191
CID: 4936422
PERFORMANCE OF THE EULAR/ACR 2019 CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN EARLY DISEASE, ACROSS SEXES AND ETHNICITIES [Meeting Abstract]
Johnson, S.; Brinks, R.; Costenbader, K.; Daikh, D.; Mosca, M.; Ramsey-Goldman, R.; Smolen, J. S.; Wofsy, D.; Boumpas, D.; Kamen, D. L.; Jayne, D.; Cervera, R.; Costedoat-Chalumeau, N.; Diamond, B.; Gladman, D. D.; Hahn, B. H.; Hiepe, F.; Jacobsen, S.; Khanna, D.; Lerstrom, K.; Massarotti, E.; Mccune, W. J.; Ruiz-Irastorza, G.; Sanchez-Guerrero, J.; Schneider, M.; Urowitz, M. B.; Bertsias, G.; Hoyer, B. F.; Leuchten, N.; Tani, C.; Tedeschi, S.; Touma, Z.; Schmajuk, G.; Anic, B.; Assan, F.; Chan, T.; Clarke, A. E.; Crow, M. K.; Czirjak, L.; Doria, A.; Graninger, W.; Halda-Kiss, B.; Hasni, S.; Izmirly, P.; Jung, M.; Kumanovics, G.; Mariette, X.; Padjen, I.; Pego-Reigosa, J. M.; Romero-Diaz, J.; Rua-Figueroa, I.; Seror, R.; Stummvoll, G.; Tanaka, Y.; Tektonidou, M.; Vasconcelos, C.; Vital, E.; Wallace, D. J.; Yavuz, S.; Meroni, P. L.; Fritzler, M.; Naden, R.; Doerner, T.; Aringer, M.
ISI:000555905001115
ISSN: 0003-4967
CID: 4562892
Pregnancy outcomes in mixed connective tissue disease: a multicentre study
Radin, Massimo; Schreiber, Karen; Cuadrado, Maria José; Cecchi, Irene; Andreoli, Laura; Franceschini, Franco; Caleiro, Teresa; Andrade, Danieli; Gibbone, Elena; Khamashta, Munther; Buyon, Jill; Izmirly, Peter; Aguirre, Maria Angeles; Benedetto, Chiara; Roccatello, Dario; Marozio, Luca; Sciascia, Savino
OBJECTIVES/OBJECTIVE:In this study we aimed to investigate foetal and maternal pregnancy outcomes from a large multicentre cohort of women diagnosed with MCTD and anti-U1RNP antibodies. METHODS:This multicentre retrospective cohort study describes the outcomes of 203 pregnancies in 94 consecutive women ever pregnant who fulfilled the established criteria for MCTD with confirmed U1RNP positivity. RESULTS:The foetal outcomes in 203 pregnancies were as follows: 146 (71.9%) live births, 38 (18.7%) miscarriages (first trimester pregnancy loss of <12 weeks gestation), 18 (8.9%) stillbirths (pregnancy loss after 20 weeks gestation) and 11 (5.4%) cases with intrauterine growth restriction. Maternal pregnancy outcomes were as follows: 8 (3.9%) developed pre-eclampsia, 2 (0.9%) developed eclampsia, 31 (15.3%) developed gestational hypertension and 3 (1.5%) developed gestational diabetes. Women with MCTD and aPL and pulmonary or muscular involvement had worse foetal outcomes compared with those without. Moreover, we report a case of complete congenital heart block (0.45%) and a case of cutaneous neonatal lupus, both born to a mother with positive isolated anti-U1RNP and negative anti-Ro/SSA antibodies. CONCLUSION/CONCLUSIONS:In our multicentre cohort, women with MCTD had a live birth rate of 72%. While the true frequency of heart block associated with anti-U1RNP remains to be determined, this study might raise the consideration of echocardiographic surveillance in this setting. Pregnancy counselling should be considered in women with MCTD.
PMID: 31079145
ISSN: 1462-0332
CID: 3909962
Author Correction: Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways
Der, Evan; Suryawanshi, Hemant; Morozov, Pavel; Kustagi, Manjunath; Goilav, Beatrice; Ranabothu, Saritha; Izmirly, Peter; Clancy, Robert; Belmont, H Michael; Koenigsberg, Mordecai; Mokrzycki, Michele; Rominieki, Helen; Graham, Jay A; Rocca, Juan P; Bornkamp, Nicole; Jordan, Nicole; Schulte, Emma; Wu, Ming; Pullman, James; Slowikowski, Kamil; Raychaudhuri, Soumya; Guthridge, Joel; James, Judith; Buyon, Jill; Tuschl, Thomas; Putterman, Chaim
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
PMID: 31605099
ISSN: 1529-2916
CID: 4130802
Salivary dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus
Clancy, R M; Marion, M C; Ainsworth, H C; Blaser, M J; Chang, M; Howard, T D; Izmirly, P M; Lacher, C; Masson, M; Robins, K; Buyon, J P; Langefeld, C D
Mothers giving birth to children with manifestations of neonatal lupus (NL) represent a unique population at risk for the development of clinically evident pathologic autoimmunity since many are asymptomatic and only become aware of anti-SSA/Ro positivity (anti-Ro+) based on heart block in their fetus. Accordingly, we hypothesized that the microbiome in saliva is associated with the development of autoreactivity and in some cases the progression in health status from benign to overt clinical disease including Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE). The study comprised a clinical spectrum of anti-Ro+ mothers, all of whom gave birth to a child with NL: 9 were asymptomatic or had an undifferentiated autoimmune disease (Asym/UAS) and 16 fulfilled criteria for SS and/or SLE. Microbial diversity was reduced across all levels from kingdom to species for the anti-Ro+ mothers vs healthy controls; however, there were no significant differences between Asym/UAS and SS/SLE mothers. Relative abundance of Proteobacteria and more specifically class Betaproteobacteria decreased with clinical severity (healthy controls < Asym/UAS < SS/SLE). These ordered differences were maintained through the taxonomic hierarchy to three genera (Lautropia, Comamonas, and Neisseria) and species within these genera (L. mirabilis, N. flavescens and N. oralis). Biometric analysis comparing von Willebrand Factor domains present in human Ro60 with L. mirabilis proteins support the hypothesis of molecular mimicry. These data position the microbiome in the development of anti-Ro reactivity and subsequent clinical spectrum of disease.
PMID: 31677965
ISSN: 1095-9157
CID: 4179102
Association between neutrophil to lymphocyte, monocyte to lymphocyte, and platelet to lymphocyte ratios and lupus disease activity and lupus nephritis [Meeting Abstract]
Carlucci, P; Luttrell-Williams, E; Bhan, R; Trad, C; El, Bannoudi H; Izmirly, P; Belmont, H M; Buyon, J; Berger, J
Background/Purpose : Subjects with Systemic Lupus Erythematosus (SLE) are at elevated risk for end-organ damage. Lupus nephritis continues to be the complication with the highest standardized mortality ratio in SLE, yet clinicians have few tools to identify patients at risk. A complete blood count is a readily available test but little is known about its usefulness in tracking lupus nephritis and activity. In recent years, neutrophil/lymphocyte (NLR), monocyte/ lymphocyte (MLR), and platelet/lymphocyte (PLR) ratios have emerged as markers of systemic inflammation. This study sought to evaluate the association between NLR, MLR, and PLR and its individual components and lupus disease activity and lupus nephritis. Methods : 25 matched healthy controls and 85 patients fulfilling ACR or SLICC criteria for SLE were enrolled in the study and demographics, disease activity, as measured by the Hybrid SLEDAI, medications, and clinical manifestations were recorded. 20 lupus patients included in the study had active lupus nephritis, as defined by proteinuria greater than 500 mg/g creatinine. A complete blood cell count was assessed on all patients and healthy controls. Patients with platelet counts less than 100K or on nonsteroidal anti-inflammatory drugs were excluded from the study. Results : Overall, SLE patients had a significantly higher PLR (p=0.0001), NLR (p=0.0003), and MLR (p=0.0035) compared to healthy controls. Lymphocyte counts alone negatively associated with SLEDAI (beta=-0.31, p=0.006) but monocyte, neutrophil, or platelet counts did not show a significant association with SLEDAI. All three ratios showed a significant positive association with SLEDAI in linear regression analysis with PLR being a better predictor than lymphocyte counts alone (beta=0.38, p< 0.0001). The associations between PLR or MLR but not NLR and SLEDAI remained significant in a multivariate linear regression model adjusting for age, race, sex, ethnicity, and medications. Specifically, the dose of glucocorticoids did not explain the clinical associations with these cellular ratios. When evaluating active lupus nephritis, PLR (p=0.118) was not significant in a logistic regression and NLR (p=0.007) and MLR (p=0.007) performed equally well. These associations between NLR or MLR and active lupus nephritis persisted in a multivariate logistic regression model adjusting for age, race, sex, ethnicity, and medications. Interestingly, lymphocyte, monocyte, neutrophil, or platelet counts alone did not associate with active lupus nephritis. Conclusion : These data suggest that by using standard clinical labs to calculate NLR, MLR, and PLR clinicians may be able to better characterize lupus activity and current lupus nephritis
EMBASE:633060629
ISSN: 2326-5205
CID: 4633352
Assessing commercial titers of anti-Ro60 and RO52 antibodies to risk stratify surveillance of anti-RO/SSA antibody positive pregnancies [Meeting Abstract]
Robins, K; Bhan, R; Trad, C; Cohen, R; Chang, M; Wainwright, B; Masson, M; Mehta-Lee, S; Izmirly, P; Clancy, R; Cuneo, B; Buyon, J
Background/Purpose : Pregnancy counseling of all anti-Ro positive women includes advice regarding the development of congenital heart block (CHB), albeit the risk is only 2% for primigravida women or those with previously unaffected offspring. Despite this low risk, the prevailing surveillance recommendation is weekly echocardiography. While evidence from basic research laboratories support that high titers of antibodies confer clinically meaningful risk, unfortunately the majority of commercial laboratories use the BioPlex assay, which provides positive and negative values with limited information on actual levels because the sera or plasma are not diluted past a specified cutoffgiven cost (e.g. values of anti-Ro inclusive of Ro52 or Ro60 by laboratories such as Quest or LabCorp provide positive as 1-8 or > 8 units with no further information). The present study was initiated to assess whether the Bio-Plex assay used by many commercial laboratories provides adequate stratification of risk for counseling regarding management. Methods : The study group comprised healthy non-pregnant donors (N = 9), healthy pregnant donors (N = 62), women testing positive for anti-Ro by commercial BioPlex but without CHB children (N = 60 SLE and 2 SS), and women with CHB children (N = 83). Anti-Ro60 reactivity was assessed using native antigen and anti-Ro52 using recombinant protein. Sera were applied to coated microtiter plates at serial dilutions ranging from 1:1000 -1:50,000 for 1h at RT and run in duplicate. Tested samples were multiplied by the dilution factor which gives an OD in the range of 0.3-0.8. Results were considered positive at 123 ELISA units (EU) for Ro60 and 215 EU for Ro52 as this represented the mean +3 SD of the values obtained for healthy control sera. Results : Of the 83 CHB mothers tested, 74 had titers of Ro60 and Ro52 > 1000 EU, in 1 anti-Ro60 was > 1000 EU and anti-52 Ro between 215 -1000, in 3 anti-Ro52 was > 1000 EU and anti-Ro60 between 300 -1000, and 1 mother had anti-Ro60 > 1000 EU and was negative for anti-Ro52. Albeit all positive, the sera from 4 CHB mothers obtained 15 years after the birth of the affected child were < 1000 EU for both anti-Ro60 and Ro52. With these results setting thresholds ( > 1000 EU in either Ro60 or Ro52 for CHB risk), we assessed patients testing positive for anti-Ro based on the BioPlex assay. Of 42 patients with values of > 8 on BioPlex testing, 14 had titers > 1000 EU for both anti-Ro60 and Ro52, 7 had anti-Ro60 > 1000 EU, and 8 had anti-Ro52 > 1000 EU. Thus, 13 of 42 (25%) with commercial Ro > 8 did not meet the threshold EU for CHB risk. Of 20 patients considered positive for anti-Ro by BioPlex with values between 1-8, none had levels of either anti-Ro60 or Ro52 at 1000 EU. No patient or healthy control testing negative by the BioPlex assay was positive for CHB risk in our ELISA. Conclusion : These data suggest that commercial testing using the BioPlex assay may fall short of stratifying risk for CHB. Women with positive values < 8 are not likely at risk, obviating the cost and burden of weekly fetal echo surveillance. Moreover, even those considered high titer on commercial testing may be at low risk supporting the need for more quantitative commercial testing than is currently available. (Figure Presented)
EMBASE:633058601
ISSN: 2326-5205
CID: 4633712
Evaluation of the transcriptome of non-lesional, non-sun exposed skin in patients with lupus nephritis [Meeting Abstract]
Suryawanshi, H; Clancy, R; Der, E; Izmirly, P; Belmont, H M; Putterman, C; Buyon, J; Tuschl, T
Background/Purpose : The impact of renal injury in lupus nephritis (LN) is widespread with consequences to resident cells in other tissue beds, even non-lesional, non-sun exposed skin. Faithful reflection of a relevant renal tissue pathway in a more readily accessible compartment would allow for less invasive diagnostic alternatives. While ongoing studies are exploiting single cell RNA sequencing to link phenotype to biotype and identify cell specific pathways in the kidney, this study was initiated to address the hypothesis that these pathways may be reflected in uninvolved skin which is more likely to be serially biopsied. Methods : Single cell RNAseq was performed on cell suspensions prepared from ~2 mm punch biopsies of nonlesional, non-sun-exposed skin from the buttocks of 5 healthy controls, 4 SLE patients without LN and 18 SLE patients with proteinuria (with skin biopsies obtained within 24 hrs of the kidney biopsy). Histology revealed Class III ( n=6 ), Class III/V or IV/V mixed ( n=11 ), Class V ( n=1 ), and nephrosclerosis ( n=1 ). Dissociation of cryostored skin biopsies with collagenase and trypsin enzymes was followed by scRNA-seq using the 10x Genomics platform using V2 and V3 reagents. Results : We obtained 8,019 and 17,655 high-quality scRNA-seq profiles from single cell suspensions of control and SLE non-lesional, non-sun-exposed skin, respectively. A graph-based clustering method was applied and identified major clusters of cells as visualized by t-distributed stochastic neighbor embedding (tSNE). Differential gene expression analysis guided by established markers revealed these cell clusters as keratinocyte (KC), one smooth muscle cell cluster (SMC), fibroblast (FB), melanocyte (MEL), vascular endothelial cells (VEC), lymphatic endothelial cells (LEC), macrophages-dendritic cells (MAC-DC), T cells (TC) and sweat gland cells (SGC) (Figure 1A). Ranking cells by abundance, the result of the SLE skin cells was KC >FB >VEC >LEC, SMC, MAC-DC, TC, MEL and SGC. Overall, samples processed using the recent V3 single cell reagent kit showed higher genes and transcript captures compared to V2. However, these samples also captured more mitochondrial transcripts (Figure 1B). An analysis of gene expression changes in KC, SMC, and VSC from the LN patients versus controls demonstrated overexpression of interferon stimulated genes. However, the degree of interferon response varied in these cell types with KCs (basal KC, p=0.00312 and hair follicle KC, p=0.000012) showing the highest response followed by VECs (p=0.0043) and SMCs (p=0.0068). In addition to the interferon response signature, VECs from the LN patients also showed upregulation of MHC-II genes such as HLA-DRB5 and HLA-DRB1, suggesting increased antigen presentation capacity (Figure 1C). Conclusion : scRNA-seq identifies major skin cell types and further clustering identifies rarer cell populations. KCs, SMCs, and VECs from the skin of LN patients reveal diverse IFN response states and additionally VECs also show higher antigen presentation potential. The V3 upgrade of 10x Genomics single cell reagents capture more genes and UMIs per cell, but also higher mitochondrial content compared to the V2 version
EMBASE:633058250
ISSN: 2326-5205
CID: 4633772